Brief report
Familial ApoB-specific familial hypobetalipoproteinemia in a patient with non-classical congenital adrenal hyperplasia
Hipobetalipoproteinemia familiar ApoB específica en una paciente con hiperplasia suprarrenal congénita no clásica
Beatriz Ramos Bachillera,
, Manuel Luque-Ramírezb,c, Carmen Rodríguez-Jiménezd, Francisco J. Arrieta Blancob,e
Corresponding author
a Servicio de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, Castilla-León, Spain
b Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, Spain
c Grupo de Investigación en Diabetes, Obesidad y Reproducción Humana, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBER de Diabetes y Enfermedades Metabólicas Asociadas, y Universidad de Alcalá, Madrid, Spain
d Department of Genetics of Metabolic Diseases, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain
e Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) Para Enfermedades Metabólicas Hereditarias, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Read
Not available
Timeswas read the article
Total PDF
Total HTML
Share statistics
array:24 [ "pii" => "S252991232400024X" "issn" => "25299123" "doi" => "10.1016/j.artere.2024.05.003" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "699" "copyright" => "Sociedad Española de Arteriosclerosis" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2024;36:128-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0214916823001171" "issn" => "02149168" "doi" => "10.1016/j.arteri.2023.12.002" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "699" "copyright" => "Sociedad Española de Arteriosclerosis" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Invest Arterioscl. 2024;36:128-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Nota clínica</span>" "titulo" => "Hipobetalipoproteinemia familiar ApoB específica en una paciente con hiperplasia suprarrenal congénita no clásica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "128" "paginaFinal" => "132" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Familial ApoB-specific familial hypobetalipoproteinemia in a patient with non-classical congenital adrenal hyperplasia" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Beatriz Ramos Bachiller, Manuel Luque-Ramírez, Carmen Rodríguez-Jiménez, Francisco J. Arrieta Blanco" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Ramos Bachiller" ] 1 => array:2 [ "nombre" => "Manuel" "apellidos" => "Luque-Ramírez" ] 2 => array:2 [ "nombre" => "Carmen" "apellidos" => "Rodríguez-Jiménez" ] 3 => array:2 [ "nombre" => "Francisco J." "apellidos" => "Arrieta Blanco" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S252991232400024X" "doi" => "10.1016/j.artere.2024.05.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S252991232400024X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916823001171?idApp=UINPBA00004N" "url" => "/02149168/0000003600000003/v2_202405090610/S0214916823001171/v2_202405090610/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2529912324000366" "issn" => "25299123" "doi" => "10.1016/j.artere.2024.06.001" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "709" "copyright" => "The Author(s)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Clin Investig Arterioscler. 2024;36:133-94" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>" "titulo" => "SEA 2024 Standards for Global Control of Vascular Risk" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "133" "paginaFinal" => "194" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 3871 "Ancho" => 2239 "Tamanyo" => 1326399 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">SCORE2 and SCORE2-OP tables for low cardiovascular risk countries.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">CV: cardiovascular; HDL: high-density lipoprotein; SCORE2: Systematic Coronary Risk Estimation 2; SCORE2-OP: Systematic Coronary Risk Estimation 2-Older Persons.</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Source: Visseren F.L.J., et al., 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC), European Heart Journal 2021; 42 (34): 3227–3337 doi:10.1093/eurheartj/ehab484. Translated and reproduced by permission of Oxford University Press on behalf of the European Society of Cardiology. OUP and European Society of Cardiology accept no responsibility or liability for the accuracy of the translation. The licensee is solely responsible for the translation in this publication/reprint.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José María Mostaza, Xavier Pintó, Pedro Armario, Luis Masana, José T. Real, Pedro Valdivielso, Teresa Arrobas-Velilla, Ramón Baeza-Trinidad, Pilar Calmarza, Jesús Cebollada, Miguel Civera-Andrés, José I. Cuende Melero, José L. Díaz-Díaz, Javier Espíldora-Hernández, Jacinto Fernández Pardo, Carlos Guijarro, Carles Jericó, Martín Laclaustra, Carlos Lahoz, José López-Miranda, Sergio Martínez-Hervás, Ovidio Muñiz-Grijalvo, José A. Páramo, Vicente Pascual, Juan Pedro-Botet, Pablo Pérez-Martínez, José Puzo" "autores" => array:27 [ 0 => array:2 [ "nombre" => "José María" "apellidos" => "Mostaza" ] 1 => array:2 [ "nombre" => "Xavier" "apellidos" => "Pintó" ] 2 => array:2 [ "nombre" => "Pedro" "apellidos" => "Armario" ] 3 => array:2 [ "nombre" => "Luis" "apellidos" => "Masana" ] 4 => array:2 [ "nombre" => "José T." "apellidos" => "Real" ] 5 => array:2 [ "nombre" => "Pedro" "apellidos" => "Valdivielso" ] 6 => array:2 [ "nombre" => "Teresa" "apellidos" => "Arrobas-Velilla" ] 7 => array:2 [ "nombre" => "Ramón" "apellidos" => "Baeza-Trinidad" ] 8 => array:2 [ "nombre" => "Pilar" "apellidos" => "Calmarza" ] 9 => array:2 [ "nombre" => "Jesús" "apellidos" => "Cebollada" ] 10 => array:2 [ "nombre" => "Miguel" "apellidos" => "Civera-Andrés" ] 11 => array:2 [ "nombre" => "José I." "apellidos" => "Cuende Melero" ] 12 => array:2 [ "nombre" => "José L." "apellidos" => "Díaz-Díaz" ] 13 => array:2 [ "nombre" => "Javier" "apellidos" => "Espíldora-Hernández" ] 14 => array:2 [ "nombre" => "Jacinto" "apellidos" => "Fernández Pardo" ] 15 => array:2 [ "nombre" => "Carlos" "apellidos" => "Guijarro" ] 16 => array:2 [ "nombre" => "Carles" "apellidos" => "Jericó" ] 17 => array:2 [ "nombre" => "Martín" "apellidos" => "Laclaustra" ] 18 => array:2 [ "nombre" => "Carlos" "apellidos" => "Lahoz" ] 19 => array:2 [ "nombre" => "José" "apellidos" => "López-Miranda" ] 20 => array:2 [ "nombre" => "Sergio" "apellidos" => "Martínez-Hervás" ] 21 => array:2 [ "nombre" => "Ovidio" "apellidos" => "Muñiz-Grijalvo" ] 22 => array:2 [ "nombre" => "José A." "apellidos" => "Páramo" ] 23 => array:2 [ "nombre" => "Vicente" "apellidos" => "Pascual" ] 24 => array:2 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" ] 25 => array:2 [ "nombre" => "Pablo" "apellidos" => "Pérez-Martínez" ] 26 => array:2 [ "nombre" => "José" "apellidos" => "Puzo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916824000172" "doi" => "10.1016/j.arteri.2024.02.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916824000172?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912324000366?idApp=UINPBA00004N" "url" => "/25299123/0000003600000003/v1_202406270520/S2529912324000366/v1_202406270520/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S2529912324000263" "issn" => "25299123" "doi" => "10.1016/j.artere.2024.05.005" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "722" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2024;36:126-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "“2024 Spanish Society of Arteriosclerosis standards for the global control of vascular risk: an essential reference document”" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "126" "paginaFinal" => "127" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Fernando Civeira, Rosa M. Sánchez-Hernández" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Fernando" "apellidos" => "Civeira" ] 1 => array:2 [ "nombre" => "Rosa M." "apellidos" => "Sánchez-Hernández" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912324000263?idApp=UINPBA00004N" "url" => "/25299123/0000003600000003/v1_202406270520/S2529912324000263/v1_202406270520/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>" "titulo" => "Familial ApoB-specific familial hypobetalipoproteinemia in a patient with non-classical congenital adrenal hyperplasia" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "128" "paginaFinal" => "132" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Beatriz Ramos Bachiller, Manuel Luque-Ramírez, Carmen Rodríguez-Jiménez, Francisco J. Arrieta Blanco" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Beatriz" "apellidos" => "Ramos Bachiller" "email" => array:1 [ 0 => "beatriz.ramos.bachiller@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Manuel" "apellidos" => "Luque-Ramírez" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Carmen" "apellidos" => "Rodríguez-Jiménez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 3 => array:3 [ "nombre" => "Francisco J." "apellidos" => "Arrieta Blanco" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, Castilla-León, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Grupo de Investigación en Diabetes, Obesidad y Reproducción Humana, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBER de Diabetes y Enfermedades Metabólicas Asociadas, y Universidad de Alcalá, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Department of Genetics of Metabolic Diseases, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) Para Enfermedades Metabólicas Hereditarias, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hipobetalipoproteinemia familiar ApoB específica en una paciente con hiperplasia suprarrenal congénita no clásica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Familial hypobetalipoproteinaemia (HBL) is a genetic disorder characterised by decreased plasma concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol, and apolipoprotein B (ApoB) below the 5th percentile of the reference population.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Although in some cases the mutation is not identified, the best characterised variants are located in the <span class="elsevierStyleItalic">APOB</span> gene; these are nonsense and frameshift mutations that result in truncated proteins.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> This specific HBL ApoB has an autosomal co-dominant inheritance and its prevalence is estimated at one in 1000–3000 individuals.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The clinical presentation depends on the number of alleles affected. Heterozygous individuals are usually asymptomatic and are identified by lipid profile. They may occasionally develop hepatic steatosis or steatorrhoea. In contrast, when the mutation is biallelic, the clinical manifestations are more florid with gastrointestinal, neurological, ophthalmological, and fat-soluble vitamin deficiencies. The definitive diagnosis is made with the analysis of mutations in the <span class="elsevierStyleItalic">APOB</span> gene located on chromosome 2 after demonstrating a family history, and ruling out other causes of abetalipoproteinaemia such as mutations in <span class="elsevierStyleItalic">PCSK9</span> and <span class="elsevierStyleItalic">MTTP</span>. Dietary restriction of long-chain triglycerides improves gastrointestinal symptoms. Essential fatty acid and fat-soluble vitamin supplementation is recommended if deficiency is detected.</p><p id="par0010" class="elsevierStylePara elsevierViewall">However, non-classical congenital adrenal hyperplasia (NCAH) is an autosomal recessive disorder that, in its most frequent form, affects the <span class="elsevierStyleItalic">CYP21A2</span> gene that codes for the enzyme 21-hydroxylase, involved in the synthesis of adrenal steroids. In contrast to the classical form, in NCAH the enzyme maintains a residual activity of 30%–50%,<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> avoiding clinical cortisol and aldosterone deficiency, but presents with hyperandrogenism. Although some patients debut with precocious puberty, the clinical presentation in most cases is clinically indistinguishable from polycystic ovary syndrome, with dermo-cosmetic involvement mainly in the form of hirsutism and/or acne, ovulatory dysfunction, and in a significant percentage of patients, multifollicular ovarian morphology on ultrasound. Diagnosis includes the demonstration of baseline 17-hydroxyprogesterone (17-OHP) concentrations above 10<span class="elsevierStyleHsp" style=""></span>ng/mL in the follicular phase of the menstrual cycle or after stimulation with 1–24 ACTH. In most NCAH subjects ACTH secretion is normal.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Adrenal hyperandrogenism is postulated to be due to an enzymatic defect with increased steroidogenic precursors and peripheral androgen conversion, also accompanied by hypersecretion of ovarian origin. Genetic diagnosis includes analysis of the <span class="elsevierStyleItalic">CYP21A2</span> locus. Deletions, conversions, and point mutations comprise 95% of the gene variants associated with CAH.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The presence of a mild mutation in at least one of both mutated alleles is associated with sufficient enzymatic capacity to prevent cortisol and aldosterone synthesis deficiency, whereas severe bi-allelic mutations lead to gluco- and mineralocorticoid deficiency, although the genotype-phenotype correlation is not absolute.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The exceptional concurrence of both entities in the same patient — according to the known prevalence of both conditions, 1 case per 1−3<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> individuals in the general population— y and the diagnostic-therapeutic implications of this have not been reported.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Clinical case</span><p id="par0020" class="elsevierStylePara elsevierViewall">A 25-year-old woman with no known drug allergies, smoker of 7–8 cigarettes/day, and a history of a 6<span class="elsevierStyleHsp" style=""></span>mm thyroid cyst in the left thyroid lobe. Her family history included a diagnosis of NCAH in her sister (<span class="elsevierStyleItalic">Ile172Asn/Val281Leu</span> genotype). The mother and father were heterozygous carriers of the mutated <span class="elsevierStyleItalic">Val281Leu</span> and <span class="elsevierStyleItalic">Ile172Asn</span> alleles, respectively. The patient was under follow-up in the reproductive endocrinology clinic at our centre for NCAH - with the same genotype as her sister - diagnosed at another centre at 7 years and 10 months of age after presenting with premature pubarche with advanced bone age and acne. Hyperandrogenaemia was found, biochemically confirming the diagnosis of NCAH and subsequently the referred genotype. Treatment with hydrocortisone was started initially, with spontaneous menarche at 13 years of age. Given the lack of hyperandrogenaemia control, hydrocortisone was replaced by evening dexamethasone at 17 years of age. At the time she was transferred to our clinic aged 18, the patient was not overweight or obese, had reached her target height, reported regular menstruation, and had no dermo-cutaneous signs of hyperandrogenism. Mild suppression of the corticotropic axis was observed (serum cortisol after conventional stimulation with 1–24 ACTH of 12μg/dL), and therefore the glucocorticoid dose was progressively reduced until a sufficient functional reserve was observed for it to be discontinued, and she remained clinically asymptomatic. During her disease progression, at the age of 22, treatment was started with a combined oral contraceptive composed of ethinylestradiol (30μg) and dienogest (2<span class="elsevierStyleHsp" style=""></span>mg) for dysmenorrhoea. In various analyses performed during the 5 years of follow-up in our adult clinic, total circulating cholesterol <150−130<span class="elsevierStyleHsp" style=""></span>mg/dL was observed (this finding was already present in analyses performed at 16 years of age); LDL-cholesterol concentrations repeatedly <30<span class="elsevierStyleHsp" style=""></span>mg/dL, HDL-cholesterol between 80 and 110<span class="elsevierStyleHsp" style=""></span>mg/dL, and circulating triglycerides <40<span class="elsevierStyleHsp" style=""></span>mg/dL, for which reason referral was decided to a specialist clinic for familial dyslipidaemia.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Targeted history taking showed that her 66-year-old father, with a history of hypertension and resolved HBV, was being followed up by the gastroenterology department for chronic diarrhoea with 5–6 watery stools per day, without pathological products with accompanying urgency, with histological data of lymphocytic colitis, as well as severe non-alcoholic hepatic steatosis, and under treatment with oral budesonide, resin-cholestyramine, loperamide on demand, and calcifediol due to vitamin D deficiency. Last lipid profile showed fasting circulating concentrations of total cholesterol 135<span class="elsevierStyleHsp" style=""></span>mg/dL, HDL 54<span class="elsevierStyleHsp" style=""></span>mg/dL, LDL 45<span class="elsevierStyleHsp" style=""></span>mg/dL, and triglycerides 177<span class="elsevierStyleHsp" style=""></span>mg/dL. No known history of cardiovascular disease in the family. On re-anamnesis, the patient presented with non-specific gastrointestinal alterations with increased gastric motility as the only noteworthy finding. The analytical parameters of liver function and fat-soluble vitamin concentrations were within the normal range. However, given the abnormalities in the lipid profile (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) and the family history, familial HBL was suspected, and a DNA study was performed on the patient, focusing on the coding region and adjacent intronic regions of the <span class="elsevierStyleItalic">APOB</span>, <span class="elsevierStyleItalic">ANGPTL3</span>, <span class="elsevierStyleItalic">PCSK9,</span> and <span class="elsevierStyleItalic">MTTP</span> genes by NGS using the Roche KAPA HyperChoice technology panel developed by the Institute of Medical and Molecular Genetics (INGEMM). MLPA was also performed with the P062-D2 kit (MRC-Holland) and subsequent analysis with Coffalyser.NET software. An interruption was found in the reading frame by premature stop codon due to a nonsense substitution at cDNA level NM_000384.2:c.7600C<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>T; amino acid change p.(Arg2534*) in exon 26 of the <span class="elsevierStyleItalic">APOB</span> gene, in heterozygosis; considered a pathogenic variant. Given this result, it was decided to extend the genetic study to her parent, pending at the time of this publication.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The patient is currently asymptomatic and does not require treatment. The analytical values are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Discussion</span><p id="par0035" class="elsevierStylePara elsevierViewall">We present the case of a patient with two rare genetic disorders. According to ICD 11, familial HBL (5C81.1) is considered a rare disease, while NCAH has an overall prevalence in our geographical area of around .1% of the general population, although it accounts for approximately 4% of the causes of hyperandrogenism in specialist clinics.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> To our knowledge, this is the first documented case of a combination of both diseases.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Several studies have investigated cardiovascular risk factors in patients with NCAH and classical CAH,<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> although the results are highly controversial,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8</span></a> and the exogenous administration of mineralo- and glucocorticoids, the dose and duration of treatment could be at the basis of some metabolic abnormalities described in adults with CAH compared to the population without functional hyperandrogenism.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> With regard to lipid profile, in most of the reported studies, patients with NCAH do not show notable differences with respect to controls without functional hyperandrogenism. In obese patients, an increase in triglycerides and lower HDL levels have been reported, probably related to excess weight and hyperandrogenism.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a> In any case, the patient presented a lipid pattern with excessively low LDL and triglyceride levels, which is not a classic presentation NCAH, in addition to fulfilling the criteria of Fredrikson et al.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> for the diagnosis of HBL, that is, low plasma concentrations, absence of secondary causes explain this abnormality (malabsorption, malnutrition, severe infections, severe liver disease), and a potentially affected first-degree relative.</p><p id="par0045" class="elsevierStylePara elsevierViewall">In familial HBL, circulating concentrations of total cholesterol, LDL, ApoB, and sometimes triglycerides, are decreased below the fifth percentile of the reference population.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In plasma ApoB is expressed in two forms: ApoB-100 and ApoB-48; both encoded by the APOB gene located on chromosome 2. ApoB-100 is expressed in the liver and is a component of VLDL, IDL and LDL; it also serves as a ligand for the LDL receptor. ApoB-48 is expressed in the intestine as part of chylomicrons.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> ApoB-specific familial HBL the mutation is located in the <span class="elsevierStyleItalic">APOB</span> gene; production of premature stop codons in the mRNA is the most frequent mutation.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Translation of these mRNAs leads to the formation of truncated ApoB that loses the ability to form plasma lipoproteins and, consequently, to export lipids from the liver and intestine to other organs. The detection of truncated ApoB in plasma suggests that the mutation is located from exon 26 to exon 29 of the <span class="elsevierStyleItalic">APOB</span> gene. Truncated ApoBs shorter than ApoB29-30, due to mutations located in the first 25 exons of the gene, are not secreted and therefore cannot be detected in plasma.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> In the patient, a mutation was detected in exon 26 due to an amino acid change causing a premature codon stop and the generation of abnormal ApoB. The case’s parent had severe fatty liver disease, which is a frequent clinical manifestation in heterozygous patients. Due to the low production rate of unmutated ApoB-100 and impaired triglyceride transport, the VLDL export system for lipids is impaired,<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> causing the accumulation of lipids in the liver. In fact, recent evidence links familial HBL to the development of cirrhosis and hepatocellular carcinoma,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> and it is advisable to monitor liver enzymes and perform imaging tests if these are elevated. Monitoring and follow-up are important, and the prognosis has been reported to be severe when the disease appears in early childhood and excellent for the moderate form without cytolysis or steatosis. However, in general, heterozygous subjects do not require any specific treatment, except for fat-soluble vitamin supplementation, if deficiency is detected, to avoid neurological complications. Stressing the fact that this condition is benign in most cases, this heterozygosity has been related to a prolonged life expectancy in probable relation to a lower risk of cardiovascular events.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Our case is the first documented case of a combination of both genetic disorders. The remoteness of the responsible genes located on 2 different chromosomes rules out a joint inheritance pattern due to linkage disequilibrium. However, hypothesising any evolutionary advantage of such a combination may be controversial, beyond the longevity observed in some heterozygous subjects with ApoB-related familial HBL, given that there is no evidence that non-classical CAH impairs the survival of subjects with it. A potential decrease in circulating androgen and progestogen concentrations secondary to decreased cholesterol concentrations, such as that observed in the first case after statin administration in functional hyperandrogenism,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> could be accompanied by an increase in fertility in these women. However, this assertion is purely speculative, especially since most women with NCAH conceive spontaneously, and functional hyperandrogenism could even be an evolutionary advantage per se.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> However, studies that are not available in successive generations of this family may shed some light on the possible intra-familial association of these mutations, as has been observed in other diseases.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conclusions</span><p id="par0055" class="elsevierStylePara elsevierViewall">We present the case of a patient with 2 genetic disorders inherited from her parents with an exceptional association. If discordant clinical signs or symptoms are detected in the first known disease, other concomitant genetic disorders should be considered. Parental genetic study and family genetic follow-up in offspring is essential to assess this association.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Funding</span><p id="par0060" class="elsevierStylePara elsevierViewall">This research has not received specific support from public sector agencies, commercial sector, or non-profit organisations.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conflict of interests</span><p id="par0065" class="elsevierStylePara elsevierViewall">The authors have no conflict of interests to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres2172841" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1841629" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2172842" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1841630" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Clinical case" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Conclusions" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflict of interests" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1841629" "palabras" => array:5 [ 0 => "Familial hypobetalipoproteinaemia" 1 => "Non-classical congenital adrenal hyperplasia" 2 => "<span class="elsevierStyleItalic">APOB</span> gene" 3 => "21-hydroxylase" 4 => "<span class="elsevierStyleItalic">CYP21A2</span>" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1841630" "palabras" => array:5 [ 0 => "Hipobetalipoproteinemia familiar" 1 => "Hiperplasia suprarrenal congénita no clásica" 2 => "Gen <span class="elsevierStyleItalic">APOB</span>" 3 => "21-hidroxilasa" 4 => "CYP21A2" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Familial hypobetalipoproteinaemia is a disorder of lipid metabolism characterized by low levels of total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. ApoB-related familial hypolipoproteinemia is an autosomal condition with a codominance inheritance pattern. Non-classical congenital adrenal hyperplasia is an autosomal recessive disorder due to mutations in the <span class="elsevierStyleItalic">CYP21A2,</span> a gene encoding for the enzyme 21-hydroxylase, which results in an androgen excess production from adrenal source. We here present the case of a 25-year-old woman with NCAH showing decreased levels of total-cholesterol, low-density lipoprotein cholesterol and triglycerides. Her parent had digestive symptoms and severe hepatic steatosis with elevated liver enzymes, as well as decreased levels of total and low-density lipoprotein cholesterol. A genetic-molecular study of the proband identified a mutation in the <span class="elsevierStyleItalic">APOB</span> gene, which allowed a diagnosis of heterozygous ApoB-related hypolipoproteinaemia to be made.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">La hipobetalipoproteinemia familiar es un trastorno del metabolismo lipídico caracterizado por niveles bajos de colesterol total, colesterol de lipoproteínas de baja densidad y apolipoproteína B. La hipobetalipoproteinemia familiar relacionada con la apolipoproteína B es una enfermedad autosómica con un patrón de herencia de codominancia. La hiperplasia suprarrenal congénita no clásica es un trastorno autosómico recesivo prevalente por mutación del gen <span class="elsevierStyleItalic">CYP21A2</span> que codifica para la enzima 21-hidroxilasa, lo que condiciona un exceso de producción de andrógenos a nivel suprarrenal. Se presenta el caso una mujer de 25 años con hiperplasia suprarrenal congénita no clásica que presenta concentraciones circulantes bajas de colesterol total, LDL-colesterol y triglicéridos. Progenitor con clínica digestiva y esteatosis hepática grave con elevación de enzimas hepáticas y concentraciones bajas de colesterol total y LDL-colesterol. Se realiza estudio genético del caso identificado una mutación en el gen <span class="elsevierStyleItalic">APOB</span> lo que permitió realizar el diagnóstico de hipobetalipoproteinemia familiar heterocigota.</p></span>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0035" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">NV: normal values.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Date (month/year) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">09/2019 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">09/2020 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">09/2021 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">11/2021 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">06/2022 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">10/2022 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total cholesterol, mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">139 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">132 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">114 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">149 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">134 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HDL-cholesterol, mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">113 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">112 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">89 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">118 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">102 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LDL-cholesterol, mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Triglycerides, mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Aspartate aminotransferase, U/L (NV 4–50 U/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alanine aminotransferase, U/L (NV 5–40 U/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">γ-glutamyl transferase, U/L (NV 7–30 U/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Apolipoprotein B, mg/dL (NV 53–182<span class="elsevierStyleHsp" style=""></span>mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vitamin A, μg/dL (NV 30–60<span class="elsevierStyleHsp" style=""></span>μg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">77.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vitamin E, μg/dL (NV 500–1800<span class="elsevierStyleHsp" style=""></span>μg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1083 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">961 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1179 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3577296.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Analytical evolution.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:13 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypotriglyceridemias/hypolipidemias" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Martínez-Hervás" 1 => "J.T. Real-Collado" 2 => "J.F. Ascaso-Gimilio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2020.12.011" "Revista" => array:6 [ "tituloSerie" => "Clin Invest Arterioscler" "fecha" => "2021" "volumen" => "33" "numero" => "Suppl 2" "paginaInicial" => "63" "paginaFinal" => "68" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Familial hypobetalipoproteinemia: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G. Schonfeld" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1194/jlr.R300002-JLR200" "Revista" => array:7 [ "tituloSerie" => "J Lipid Res" "fecha" => "2003" "volumen" => "44" "numero" => "5" "paginaInicial" => "878" "paginaFinal" => "883" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12639976" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">APOB</span>-Related Familial Hypobetalipoproteinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.R. Burnett" 1 => "A.J. Hooper" 2 => "R.A. Hegele" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "editores" => "M.P.Adam" "titulo" => "<span class="elsevierStyleItalic">APOB</span>-Related Familial Hypobetalipoproteinemia" "serieFecha" => "2021" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "E. Carmina" 1 => "D. Dewailly" 2 => "H.F. Escobar-Morreale" 3 => "F. Kelestimur" 4 => "C. Moran" 5 => "S. Oberfield" 6 => "S.F. Witchel" 7 => "R. Azziz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/humupd/dmx014" "Revista" => array:7 [ "tituloSerie" => "Hum Reprod Update" "fecha" => "2017" "volumen" => "23" "numero" => "5" "paginaInicial" => "580" "paginaFinal" => "599" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28582566" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Falhammar" 1 => "A. Nordenström" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12020-015-0656-0" "Revista" => array:7 [ "tituloSerie" => "Endocrine" "fecha" => "2015" "volumen" => "50" "numero" => "1" "paginaInicial" => "32" "paginaFinal" => "50" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26082286" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Falhammar" 1 => "H. Filipsson Nyström" 2 => "A. Wedell" 3 => "M. Thorén" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-10-0877" "Revista" => array:6 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2011" "volumen" => "164" "numero" => "2" "paginaInicial" => "285" "paginaFinal" => "293" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Obesity and Cardiometabolic risk factors in children and young adults with non-classical 21-hydroxylase deficiency" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. de Vries" 1 => "Y. Lebenthal" 2 => "M. Phillip" 3 => "S. Shalitin" 4 => "A. Tenenbaum" 5 => "R. Bello" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fendo.2019.00698" "Revista" => array:4 [ "tituloSerie" => "Front Endocrinol (Laussane)" "fecha" => "2019" "volumen" => "10" "paginaInicial" => "698" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Krysiak" 1 => "K. Kowalcze" 2 => "B. Marek" 3 => "B. Okopień" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/00015385.2019.1666964" "Revista" => array:7 [ "tituloSerie" => "Acta Cardiol" "fecha" => "2020" "volumen" => "75" "numero" => "8" "paginaInicial" => "705" "paginaFinal" => "710" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31538536" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)" "etal" => true "autores" => array:6 [ 0 => "T.S. Han" 1 => "G.S. Conway" 2 => "D.S. Willis" 3 => "N. Krone" 4 => "D.A. Rees" 5 => "R.H. Stimson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2014-1486" "Revista" => array:7 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2014" "volumen" => "99" "numero" => "8" "paginaInicial" => "E1547" "paginaFinal" => "E1555" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24878054" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Familial lipoprotein deficiency (abetalipoproteinaemia, hypobetalipoproteinaemia and Tanger disease). The metabolic basis of inherited disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.B. Stanburg" 1 => "J.B. Wyngaarden" 2 => "D.S. Fredrikson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:5 [ "fecha" => "1972" "paginaInicial" => "493" "paginaFinal" => "530" "editorial" => "McGraw Hill" "editorialLocalizacion" => "New York" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P. Tarugi" 1 => "M. Averna" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Adv Clin Chem." "fecha" => "2011" "volumen" => "54" "paginaInicial" => "81" "paginaFinal" => "107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21874758" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of atorvastatin on testosterone levels" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.I. Shawish" 1 => "B. Bagheri" 2 => "V.M. Musini" 3 => "S.P. Adams" 4 => "J.M. Wright" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD013211.pub2" "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2021" "volumen" => "1" "numero" => "1" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H.F. Escobar-Morreale" 1 => "M. Luque-Ramírez" 2 => "J.L. San Millán" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/er.2004-0004" "Revista" => array:6 [ "tituloSerie" => "Endocr Rev" "fecha" => "2005" "volumen" => "26" "numero" => "2" "paginaInicial" => "251" "paginaFinal" => "282" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25299123/0000003600000003/v1_202406270520/S252991232400024X/v1_202406270520/en/main.assets" "Apartado" => array:4 [ "identificador" => "64742" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Clinical Report" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003600000003/v1_202406270520/S252991232400024X/v1_202406270520/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S252991232400024X?idApp=UINPBA00004N" ]